

Italy Blood Glucose Monitoring - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

Market Report | 2024-02-17 | 70 pages | Mordor Intelligence

AVAILABLE LICENSES:

- Single User License \$4750.00
- Team License (1-7 Users) \$5250.00
- Site License \$6500.00
- Corporate License \$8750.00

Report description:

The Italy Blood Glucose Monitoring Market size is estimated at USD 647.77 million in 2024, and is expected to reach USD 974.02 million by 2029, growing at a CAGR of 8.5% during the forecast period (2024-2029).

The Italian Association of Diabetes Doctors (AMD) conducted a survey among its members between February and March 2021 to assess the impact of the SARS-CoV-2 pandemic on the volume of care provided by diabetes services in Italy, as well as to analyse the measures implemented during the national lockdown. Urban health initiatives to promote healthy lifestyles through planning. Individuals' ability to understand, access, and use information in ways that promote and maintain good health is referred to as health literacy. Italy has joined the Action Network on Measuring Population and Organizational Health Literacy (M-POHL), which conducted a survey between 2019 and 2021 to establish a baseline level of health literacy that can be used to plan health policy measures to improve health literacy and track the health outcomes of such measures over time.

The International Diabetes Federation (IDF) estimated in 2021 that diabetes affected nearly 10% of the global adult population (536.6 million people), with 1.2 million children and adolescents (aged 19) suffering from type 1 diabetes. In Italy, the percentages are lower: 5.6% according to the National Institute of Statistics (ISTAT), and 4.7% according to data collected by the PASSI surveillance system among adults aged 18-69 years. ISTAT and PASSI both discovered that prevalence was higher in the southern regions than in the central and northern regions.

Italy Blood Glucose Monitoring Market Trends

Increasing Type-1 diabetes population across Italy

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Diabetes mellitus affected nearly 3.8 million Italians in the current year. This was a significant increase from 2010, when 2.9 million people were affected by the disease. Over the ten years under consideration, the number of cases fluctuated along a general upward trend before peaking in 2021. The number of cases was proportional to the age of the patients. Diabetes was, in fact, much more common among the elderly than among the younger. Diabetes mellitus will affect approximately 1.1 million people aged 65 to 74 and approximately 1.4 million aged 75 and up in Italy in 2021. Diabetes affects both men and women equally. However, the number of females who died due to diabetes mellitus was greater than that of males. Indeed, diabetes claimed the lives of over 11.7 thousand women in 2019. Diabetes poses several challenges for both the NHS and Italian society. The greatest challenge is the rising prevalence of diabetes, which poses real health and economic threat to the Italian health system in the future. Prevalence has steadily increased over the last decade and is expected to rise further. It has been stated that if prevalence continues to rise at this rate, the future impact on society and the economy will be unsustainable. The aging population and rising obesity are major contributors to rising prevalence. If an aging population is difficult. Obesity has increased in recent years, as evidenced by the AMD Annals, owing primarily to unhealthy lifestyle choices such as poor diet and insufficient physical activity. Obesity is so closely linked to diabetes that the two conditions have been dubbed "diabesity controlling." Meeting the demand for diabetes care is becoming increasingly difficult as diabetes prevalence rises, with diabetes centers struggling to care for an increasing number of diabetic patients even though diabetes centers are geographically distributed evenly.

About 9.9% of the Italian population has diabetes as of 2021. The rate of newly diagnosed Type 1 and Type 2 diabetes cases is seen to increase, mainly due to obesity, unhealthy diet, and physical inactivity. The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure are indications of the increasing usage of diabetic care products. In May 2021, the World Health Assembly agreed on a Resolution on strengthening the prevention and control of diabetes. It recommends action in areas including increasing access to insulin, promoting convergence and harmonization of regulatory requirements for insulin and other medicines and health products for the treatment of diabetes, and assessing the feasibility and potential value of establishing a web-based tool to share information relevant to the transparency of markets for diabetes medicines and health products.

Continuous Glucose Monitoring Holds Highest CAGR in Italy Blood Glucose Monitoring Market.

The COVID-19 pandemic emphasizes the need for good glycemic control in patients with diabetes, largely because most observational studies have reported that poorly controlled diabetes is associated with a higher risk of hospitalization and death from a viral illness. The frequency of monitoring glucose levels depends on the type of diabetes, which varies from patient to patient. Type-1 diabetic patients need to check their blood glucose levels regularly to monitor their blood glucose levels and adjust the insulin dosing accordingly. The current CGM devices show a detailed representation of blood glucose patterns and tendencies compared to a routine check of glucose levels at set intervals. Furthermore, the current continuous glucose monitoring devices can either retrospectively display the trends in blood glucose levels by downloading the data or give a real-time picture of glucose levels through receiver displays.

The use of CGM by Type-1 diabetic patients is very less as compared to Type-2 diabetic patients. But the expenditure of Type-1 diabetic patients on these devices is nearly double that of Type-2 diabetics. The newest CGM models, the Abbott Freestyle Libre and the Dexcom G6, overcame many technical barriers. However, high costs and uncertainties about their efficacy and necessity have kept CGM from being widely used by people with Type-2 diabetes. Continuous glucose monitoring devices are becoming cheaper with new technologies, like cell phone integration.

Italy Blood Glucose Monitoring Industry Overview

The blood glucose monitoring market is highly fragmented, with few major manufacturers present in the market. The CGM devices market is dominated by major players like Dexcom, Medtronic, Abbott, and Senseonics. The market for BGM devices

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

comprises more generic players like Roche, LifeScan, Arkray, Ascensia, etc. Technological innovations in the recent past helped companies to strengthen their market presence.

Additional Benefits:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

Table of Contents:

1 INTRODUCTION

- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

- 4.1 Market Overview
- 4.2 Drivers
- 4.3 Restraints
- 4.4 Porter's Five Forces Analysis
 - 4.4.1 Bargaining Power of Suppliers
 - 4.4.2 Bargaining Power of Consumers
 - 4.4.3 Threat of New Entrants
 - 4.4.4 Threat of Substitute Products and Services
 - 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

- 5.1 Self-monitoring blood glucose devices
 - 5.1.1 Glucometer Devices
 - 5.1.2 Test Strips
 - 5.1.3 Lancets
- 5.2 Continuous blood glucose monitoring devices
 - 5.2.1 Sensors
 - 5.2.2 Durables (Receivers and Transmitters)

6 MARKET INDICATORS

- 6.1 Type-1 Diabetes population
- 6.2 Type-2 Diabetes population

7 COMPETITIVE LANDSCAPE

- 7.1 COMPANY PROFILES
 - 7.1.1 Abbott Diabetes Care
 - 7.1.2 Roche Holding AG
 - 7.1.3 LifeScan
 - 7.1.4 Dexcom Inc.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.1.5 Medtronic PLC
- 7.1.6 Arkray Inc.
- 7.1.7 Ascensia Diabetes Care
- 7.1.8 Agamatrix Inc.
- 7.1.9 Bionime Corporation
- 7.1.10 Acon Laboratories Inc.
- 7.1.11 Trivida Functional Medicine
- 7.1.12 Senseonics
- 7.2 COMPANY SHARE ANALYSIS
- 7.2.1 Self-monitoring Blood Glucose Devices
 - 7.2.1.1 Abbott Diabetes Care
 - 7.2.1.2 Roche Holding AG
 - 7.2.1.3 LifeScan
 - 7.2.1.4 Others
- 7.2.2 Continuous Glucose Monitoring Devices
 - 7.2.2.1 Dexcom Inc.
 - 7.2.2.2 Medtronic PLC
 - 7.2.2.3 Abbott Diabetes Care

8 MARKET OPPORTUNITIES AND FUTURE TRENDS

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Italy Blood Glucose Monitoring - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

Market Report | 2024-02-17 | 70 pages | Mordor Intelligence

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4750.00
	Team License (1-7 Users)	\$5250.00
	Site License	\$6500.00
	Corporate License	\$8750.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-09"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com
www.scotts-international.com